Канал: Silas Inman

Immunotherapy Induces Responses in Subtypes of Sarcomas

Immunotherapy Induces Responses in Subtypes of Sarcomas

mCRC Treatment: Potential Game Changers

mCRC Treatment: Potential Game Changers

Continuum of Care Concept in mCRC

Continuum of Care Concept in mCRC

mCRC: Second-Line Treatment Decisions

mCRC: Second-Line Treatment Decisions

mCRC: Best Approaches to Frontline Therapy

mCRC: Best Approaches to Frontline Therapy

mCRC: Third-Line Treatment Decisions

mCRC: Third-Line Treatment Decisions

mCRC: Sequencing With Regorafenib or TAS-102

mCRC: Sequencing With Regorafenib or TAS-102

Potential With Frontline Cabozantinib Plus Nivolumab in Advanced RCC

Potential With Frontline Cabozantinib Plus Nivolumab in Advanced RCC

Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma

Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma

COMBI-AD and BRIM8 Studies in Melanoma

COMBI-AD and BRIM8 Studies in Melanoma

Considerations When Using Chemotherapy to Treat Patients With Breast Cancer

Considerations When Using Chemotherapy to Treat Patients With Breast Cancer

Eileen M. O’Reilly, MD: Impact of Effective Therapies on Treatment

Eileen M. O’Reilly, MD: Impact of Effective Therapies on Treatment

Eileen M. O’Reilly, MD: Options for Patient Going Forward

Eileen M. O’Reilly, MD: Options for Patient Going Forward

Eileen M. O’Reilly, MD: Importance of CA19-9 and Albumin Markers

Eileen M. O’Reilly, MD: Importance of CA19-9 and Albumin Markers

Eileen M. O’Reilly, MD: Role of Liposomal in Nanoliposomal Irinotecan

Eileen M. O’Reilly, MD: Role of Liposomal in Nanoliposomal Irinotecan

Eileen M. O’Reilly, MD: Expected Response with Liposomal Irinotecan

Eileen M. O’Reilly, MD: Expected Response with Liposomal Irinotecan

Eileen M. O’Reilly, MD: Aligning Treatment With Updates in NCCN Guidelines

Eileen M. O’Reilly, MD: Aligning Treatment With Updates in NCCN Guidelines

George P. Kim, MD: Impact of Effective Therapies on Treatment

George P. Kim, MD: Impact of Effective Therapies on Treatment

George P. Kim, MD: Options for Patient Going Forward

George P. Kim, MD: Options for Patient Going Forward

George P. Kim, MD: Importance of CA19-9 and Albumin Markers

George P. Kim, MD: Importance of CA19-9 and Albumin Markers

George P. Kim, MD: Role of Liposomal in Nanoliposomal Irinotecan

George P. Kim, MD: Role of Liposomal in Nanoliposomal Irinotecan

George P. Kim, MD: Expected Response with Liposomal Irinotecan

George P. Kim, MD: Expected Response with Liposomal Irinotecan

George P. Kim, MD: Aligning Treatment With Updates in NCCN Guidelines

George P. Kim, MD: Aligning Treatment With Updates in NCCN Guidelines

Dr. Charles Ryan Abiraterone Acetate in Elderly mCRPC Patients

Dr. Charles Ryan Abiraterone Acetate in Elderly mCRPC Patients

Minesh Mehta

Minesh Mehta

Dr. Michael Manns on the Link Between Hepatitis C And Hepatocellular Carcinoma

Dr. Michael Manns on the Link Between Hepatitis C And Hepatocellular Carcinoma

Dr. Andrea Apollo On Avelumab and its Effect on Locally Advanced or Metastatic Urothelial Carcinoma

Dr. Andrea Apollo On Avelumab and its Effect on Locally Advanced or Metastatic Urothelial Carcinoma

Expanded Access Program of Radium-223 in Prostate Cancer

Expanded Access Program of Radium-223 in Prostate Cancer

Dr. Perez Discusses a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial

Dr. Perez Discusses a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial